Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.

Bone - 1 Jul 2014

Boyce Rogely W, Varela Aurore, Chouinard Luc, Bussiere Jeanine L, Chellman Gary J, Ominsky Michael S, Pyrah Ian T

Abstract excerpt

RANKL is a key regulator of bone resorption and osteoclastogenesis. Denosumab is a fully human IgG2 monoclonal antibody that inhibits bone resorption by binding and inhibiting the activity of RANKL. To determine the effects of denosumab on pre- and postnatal skeletal growth and development, subcutaneous injections of 0 (control) or 50 mg/kg/month denosumab were given to pregnant cynomolgus monkeys from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Bone Remodeling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Macaca fascicularis

Share to Osteoclasts

Share to Osteopetrosis

Share to Pregnancy

Share to Prenatal Exposure Delayed Effects

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 24727159
DOI: 10.1016/j.bone.2014.04.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period.PMID 24727159Read ↗

The skeletal phenotype of intermediate GM1 gangliosidosis: Clinical, radiographic and densitometric features, and implications for clinical monitoring and intervention.Semantic proximity Read ↗

Increased Osteoclast Activity Contributes to Bone Resorption and Osteopenia in a Rett Syndrome Mouse ModelSemantic proximity Read ↗

RANK-L and RANK: T Cells, Bone Loss, and Mammalian EvolutionSemantic proximity Read ↗

The heterogeneity of the osteopetroses reflects the diversity of cellular influences during skeletal development.Semantic proximity Read ↗

Macrophage colony-stimulating factor and receptor activator NF-kappaB ligand fail to rescue osteoclast-poor human malignant infantile osteopetrosis in vitro.Semantic proximity Read ↗

Interpretation of skeletal variations for human risk assessment: delayed ossification and wavy ribsSemantic proximity Read ↗

Pregnancy and Lactation Associated Bone FragilitySemantic proximity Read ↗

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.Semantic proximity Read ↗

Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations.Semantic proximity Read ↗

Lactation induces increases in the RANK/RANKL/OPG system in maxillary bone.Semantic proximity Read ↗

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses.Semantic proximity Read ↗

Molecular mechanisms of bone resorptionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.